Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver DiseaseSJOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICSIF3.82024-04-010OAAI
The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH ModelBIOMEDICINESIF3.92021-01-0950OAAI
How to develop a differentiated FXR agonist: GS-9674 shows a reduced side effect profile in mice, monkeys amd human phase I studies compared to its predecessor Px-102JOURNAL OF HEPATOLOGYIF332019-04-011PREAI
LXR inverse agonists reduce steatosis and fibrosis in the STAM mouse model but also improve insulin sensitivity in a high fat diet mouse clamp studyJOURNAL OF HEPATOLOGYIF332019-04-010PREAI
The FXR agonist GS-9674 reduces fibrosis and portal hypertension in a rat model of NASHJOURNAL OF HEPATOLOGYIF332018-04-014PREAI
LXR inverse agonists inhibit de novo lipogenesis and reduce intestinal lipid and cholesterol absorption in a NAFLD mouse modelJOURNAL OF HEPATOLOGYIF332018-04-010PREAI
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunctionJOURNAL OF HEPATOLOGYIF332017-04-01134OAAI
Anti-steatotic effects in conjunction with lowering of PNPLA3 mRNA exerted by LXR inverse agonists in human hepatocytes and in rodent models of non-alcoholic fatty liver diseaseJOURNAL OF HEPATOLOGYIF332017-01-010PREAI
FROM MICE TO MEN - CHANGES IN FGF15/19 EXPRESSION AND BILE ACID LEVELS AS SENSITIVE MARKERS OF PHARMACOLOGICAL FXR ACTIVATION; RESULTS FROM HUMAN PHASE I AND ANIMAL STUDIES USING THE POTENTAND SELECTIVE FXR AGONIST PX-102JOURNAL OF HEPATOLOGYIF332016-01-010PREAI
FXR AGONISM BY GS-9674 DECREASES STEATOSIS AND FIBROSIS IN A MURINE MODEL OF NASHGS-9674对FXR的激动作用可降低NASH小鼠模型的脂肪变性和纤维化JOURNAL OF HEPATOLOGYIF332016-01-0116PREAI
THE NON-STEROIDAL FXR AGONIST GS-9674 REDUCES LIVER FIBROSIS AND AMELIORATES PORTAL HYPERTENSION IN A RAT NASH MODELJOURNAL OF HEPATOLOGYIF332016-01-018PREAI
THE FXR AGONIST PX20606 REDUCES LIVER DAMAGE, FIBROSIS AND PORTAL HYPERTENSION IN CIRRHOTIC RATSJOURNAL OF HEPATOLOGYIF332015-04-013PREAI
The nuclear bile acid receptor FXR controls the liver derived tumor suppressor histidine-rich glycoproteinINTERNATIONAL JOURNAL OF CANCERIF4.72014-11-1317OAAI
A Novel Pex14 Protein-interacting Site of Human Pex5 Is Critical for Matrix Protein Import into PeroxisomesJOURNAL OF BIOLOGICAL CHEMISTRYIF3.92014-01-0163OAAI
Synthetic Farnesoid X Receptor Agonists Induce High-Density Lipoprotein-Mediated Transhepatic Cholesterol Efflux in Mice and Monkeys and Prevent Atherosclerosis in Cholesteryl Ester Transfer Protein Transgenic Low-Density Lipoprotein Receptor (-/-) MiceJOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICSIF3.82012-12-01110OAAI
FXR AGONISTS PREVENT STEATOSIS, HEPATOCYTE DEATH AND PROGRESSION OF NASH TOWARDS HCC IN A HYPOINSULINAEMIC MOUSE MODEL OF PROGRESSIVE LIVER DISEASEJOURNAL OF HEPATOLOGYIF332012-04-010PREAI
NOVEL FXR AGONISTS WITH POTENT LIPID LOWERING, INSULIN SENSITISING, ANTI-INFLAMMATORY AND ANTI-FIBROTISATION EFFECTS IN MOUSE MODELS OF METABOLIC SYNDROME AND NASHJOURNAL OF HEPATOLOGYIF332011-03-013PREAI
Membrane association of the cycling peroxisome import receptor Pex5pJOURNAL OF BIOLOGICAL CHEMISTRYIF3.92006-09-0196OAAI
Pex5p, the peroxisomal cycling receptor, is a monomeric non-globular proteinJOURNAL OF BIOLOGICAL CHEMISTRYIF3.92005-07-0151OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向